Ranibizumab for the treatment of wet AMD: a summary of real-world studies.
about
Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek ExpertsFeasibility of Use of a Mobile Application for Nutrition Assessment Pertinent to Age-Related Macular Degeneration (MANAGER2)24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseasesAnti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Ig-like domain 6 of VCAM-1 is a potential therapeutic target in TNFα-induced angiogenesisTREATMENT PATTERNS AND 2-YEAR VISION OUTCOMES WITH BEVACIZUMAB IN DIABETIC MACULAR EDEMA: An Analysis From a Large U.S. Integrated Health Care System.Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration.Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update.Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy.Real world evidence of use of anti-VEGF therapy in Denmark.Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan.Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy.
P2860
Q26749615-A2EF6BA7-CEB2-4648-81DA-F25D2DCBF4F0Q33452521-184EECE5-F12F-4EC1-83DE-6A44990D4C44Q33612736-F8C845FF-7B34-4E85-AF6E-53E54BCF1649Q33840787-F33CC6FB-8C7D-4455-AE11-A857A9095834Q34558187-2032BE1C-F0AE-4901-AF84-495415A08C29Q37680056-D4874DCF-53C0-4DB4-99F0-B914CF0A06E4Q38630749-63005AD6-8D8E-4556-8E54-CFC59F87DC19Q38712425-89B50A73-B002-43CD-AA0F-5DCB1E707FD3Q47133884-073C283F-771A-4961-8488-40CB4D551D65Q47936744-0A72DE50-6E32-4774-BB9D-34FAEBE41132Q50571685-EAD56FFB-338A-48D2-8D4C-3FF0B0970104Q55009931-891092FC-57D0-4C62-A393-4D036E33864AQ55053504-3E9A462F-0B39-4D17-BDCD-424E9B2A0B7C
P2860
Ranibizumab for the treatment of wet AMD: a summary of real-world studies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ranibizumab for the treatment of wet AMD: a summary of real-world studies.
@en
type
label
Ranibizumab for the treatment of wet AMD: a summary of real-world studies.
@en
prefLabel
Ranibizumab for the treatment of wet AMD: a summary of real-world studies.
@en
P2860
P356
P1433
P1476
Ranibizumab for the treatment of wet AMD: a summary of real-world studies.
@en
P2093
P2860
P2888
P304
P356
10.1038/EYE.2015.217
P577
2015-12-04T00:00:00Z
P6179
1044752742